The estimated Net Worth of Capital Partners Iii, Llcen... is at least $202 Million dollars as of 2 November 2018. Capital Llcen owns over 533,333 units of Axonics Inc stock worth over $201,607,977 and over the last 6 years Capital sold AXNX stock worth over $0.
Capital has made over 1 trades of the Axonics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Capital bought 533,333 units of AXNX stock worth $7,999,995 on 2 November 2018.
The largest trade Capital's ever made was buying 533,333 units of Axonics Inc stock on 2 November 2018 worth over $7,999,995. On average, Capital trades about 533,333 units every 0 days since 2018. As of 2 November 2018 Capital still owns at least 2,933,333 units of Axonics Inc stock.
You can see the complete history of Capital Llcen stock trades at the bottom of the page.
Over the last 6 years, insiders at Axonics Inc have traded over $108,010,643 worth of Axonics Inc stock and bought 4,672,163 units worth $70,180,620 . The most active insiders traders include Asset Management, Lp Chen B..., Shahzad Malik, and Geoff Pardo. On average, Axonics Inc executives and independent directors trade stock every 15 days with the average trade being worth of $4,280,711. The most recent stock trade was executed by Raymond W Cohen on 24 July 2024, trading 103,896 units of AXNX stock currently worth $2,383,374.
axonics modulation technologies, inc is a privately-held medical device company developing an innovative neuromodulation platform based on a miniaturized rechargeable fully-implantable ipg licensed from the alfred mann foundation. the axonics sacral neuromodulation system is designed to improve the experience of both clinicians and patients suffering from urinary and fecal dysfunction.
Axonics Inc executives and other stock owners filed with the SEC include: